Perceptive Advisors LLC purchased a new stake in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 10,769 shares of the biopharmaceutical company’s stock, valued at approximately $540,000.

Other institutional investors have also added to or reduced their stakes in the company. Tower Research Capital LLC TRC raised its stake in Esperion Therapeutics by 69,371.4% during the second quarter. Tower Research Capital LLC TRC now owns 4,863 shares of the biopharmaceutical company’s stock valued at $225,000 after purchasing an additional 4,856 shares in the last quarter. Aperio Group LLC bought a new position in Esperion Therapeutics during the second quarter valued at $249,000. SG Americas Securities LLC increased its position in Esperion Therapeutics by 74.5% during the second quarter. SG Americas Securities LLC now owns 7,008 shares of the biopharmaceutical company’s stock valued at $324,000 after acquiring an additional 2,991 shares during the last quarter. Voya Investment Management LLC increased its position in Esperion Therapeutics by 12.7% during the second quarter. Voya Investment Management LLC now owns 7,148 shares of the biopharmaceutical company’s stock valued at $331,000 after acquiring an additional 806 shares during the last quarter. Finally, US Bancorp DE increased its position in Esperion Therapeutics by 1.1% during the second quarter. US Bancorp DE now owns 9,856 shares of the biopharmaceutical company’s stock valued at $457,000 after acquiring an additional 104 shares during the last quarter. 92.27% of the stock is currently owned by institutional investors.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) opened at $56.97 on Monday. Esperion Therapeutics, Inc. has a 1-year low of $10.71 and a 1-year high of $65.20.

Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.86) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.79) by ($0.07). During the same period in the previous year, the company posted ($0.77) EPS. equities analysts anticipate that Esperion Therapeutics, Inc. will post -7.3 earnings per share for the current fiscal year.

A number of research analysts have weighed in on ESPR shares. Northland Securities reiterated a “buy” rating and set a $72.00 price objective on shares of Esperion Therapeutics in a research report on Wednesday, October 4th. Chardan Capital reiterated a “neutral” rating and set a $75.00 price objective (up previously from $20.00) on shares of Esperion Therapeutics in a research report on Tuesday, December 5th. Cowen started coverage on shares of Esperion Therapeutics in a research report on Thursday, September 7th. They set an “outperform” rating and a $64.00 price objective on the stock. Stifel Nicolaus reiterated a “buy” rating and set a $70.00 price objective on shares of Esperion Therapeutics in a research report on Wednesday, October 4th. Finally, Zacks Investment Research upgraded shares of Esperion Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, August 23rd. Eight research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $60.15.

In other news, Director Nicole Vitullo sold 9,326 shares of the company’s stock in a transaction dated Wednesday, December 6th. The shares were sold at an average price of $53.85, for a total value of $502,205.10. Following the transaction, the director now directly owns 2,472 shares in the company, valued at $133,117.20. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 32.50% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another domain, it was stolen and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/12/11/perceptive-advisors-llc-takes-position-in-esperion-therapeutics-inc-espr.html.

About Esperion Therapeutics

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Want to see what other hedge funds are holding ESPR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Esperion Therapeutics, Inc. (NASDAQ:ESPR).

Institutional Ownership by Quarter for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Stock Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related stocks with our FREE daily email newsletter.